Insulin like growth factors axis and growth disorders
The growth hormone-insulin like growth factor (GH-IGF) axis plays a crucial role in the regulation of growth. Initially considered to be a mediator of growth hormone actions, IGF axis has been established as an independent endocrine system with wide array of actions. Recent advances have led to tremendous increase in the clinical utility of the IGF axis. IGF-based investigations (IGF1 and IGF binding protein 3) are now replacing GH-based investigations for evaluation and monitoring of disorders of the GH-IGF axis. IGF therapy has been successfully utilized in growth hormone insensitivity syndrome and GHD type 1B. The possibility of IGF axis as therapeutic options is being explored in wide variety of disorders like hypoxic-ischemic encephalopathy, Alzheimer's disease and psoriasis.
Key wordsGrowth disorders Insulin like growth factor binding proteins (IGFBP) Insulin like growth factors (IGF)
Unable to display preview. Download preview PDF.
- 1.Rosenfield GR, Cohen P. Disorders of growth hormone/ insulin like growth factor and action. In Sperling MA, ed.Pediatric Endocrinology. 2nd edn. Philadelphia; WB Saunders, 2002; 211–288.Google Scholar
- 5.Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin.J Biol Chem 1978; 25: 2769–2776.Google Scholar
- 13.Blum WF, Cotterill AM, Postel-Vinay MCet al. Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Grwoth Hormone Insensitivity Syndromes.Acta Paediatr Suppl 1994; 399: 117–124.PubMedGoogle Scholar
- 18.Guevara-Aguirre J, Rosenbloom AL, Vasconez Oet al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.J Clin Endocrinol Metab 1997; 82: 629–633.PubMedCrossRefGoogle Scholar
- 20.Backeljauw PF, Underwood LE, GHIS Collaborative Group. Growth hormone insensitivity syndrome. Therapy for 6.5–7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.J Clin Endocrinol Metab 2001; 86: 1504–1510.PubMedCrossRefGoogle Scholar